Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA).

Fiche publication

Date publication

février 2020

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc

Tous les auteurs :
Patrikidou A, Chaigneau L, Isambert N, Kitikidou K, Shanley R, Ray-Coquard I, Valentin T, Malivoir B, Laigre M, Bay JO, Moureau-Zabotto L, Bompas E, Piperno-Neumann S, Penel N, Alcindor T, Guillemet C, Duffaud F, Hügli A, Le Pechoux C, Dhermain F, Blay JY, Sperduto PW, Le Cesne A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32050939

Résumé

Brain metastases from sarcomatous lesions pose a management challenge owing to their rarity and the histopathological heterogeneity. Prognostic indices such as the Graded Prognostic Assessment (GPA) index have been developed for several primary tumour types presenting with brain metastases (e.g. lung, breast, melanoma), tailored to the specifics of different primary histologies and molecular profiles. Thus far, a prognostic index to direct treatment decisions is lacking for adult sarcoma patients with brain metastases.